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Recent studies suggest a role for the microbiota in autism spectrum disorders (ASD), potentially arising from
their role in modulating the immune system and gastrointestinal (GI) function or from gutbrain interactions
dependent or independent from the immune system. GI problems such as chronic constipation and/or diarrhea
are common in children with ASD, and significantly worsen their behavior and their quality of life. Here we first
summarize previously published data supporting that GI dysfunction is common in individuals with ASD and
the role of the microbiota in ASD. Second, by comparing with other publically available microbiome datasets,
we provide some evidence that the shifted microbiota can be a result of westernization and that this shift could
also be framing an altered immune system. Third, we explore the possibility that gutbrain interactions could
also be a direct result of microbially produced metabolites.
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T
here is a general consensus that gastrointestinal
(GI) problems are common in individuals with
autism spectrum disorders (ASD) (1), although
the exact percentage varies from study to study and de-
pends on the age of the study population. Population-
based studies, which do not directly select or bias their
samples, are the best way to determine incidence. In a study
of 137 children with ASD, 24% had a history of at least
one GI symptom, with diarrhea being the most prevalent 
occurring in 17% of individuals (2). Similarly, a study of
172 children with ASD found 22.7% were positive for GI
distress, primarily with diarrhea and/or constipation (3).
A study of 160 children with ASD found 59% had GI
dysfunction with diarrhea or unformed stools, constipa-
tion, bloating, and/or gastroesophageal reflux (GERD) (4).
A study of 150 children [50 children with ASD, 50 controls,
and 50 children with other developmental disabilities (DD)]
found that 70% of children with ASD presented GI symp-
toms, compared to 28% of typically developing children and
42% of children with DD (5). A study by Adams et al. (6)
where 51 children with ASD were compared to 40 typical
healthy controls aged 315 found that 63% of children with
autism had moderate or severe chronic diarrhea and/or
constipation, versus 2% of the control children. A study of
960 children with ASD, DD, and typical development
found that children with ASD and DD had at least one
reported GI symptom, and that children with ASD that
had common occurrences of abdominal pain, gases, diarrhea,
and constipation; scored worse on four behavioral mea-
surements assessed by the Aberrant Behavior Check-
list (ABC) (7). A study that compared 121 children with
ASD to 242 matched controls found significantly higher

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constipation (33.9% vs. 17.6%) and food selectivity (24.5%
vs. 16.1%) but not diarrhea, abdominal bloating, or reflux
in the ASD cohort (8). Based on this finding, the authors
suggested that GI issues with ASD may be primarily neu-
robehavioral rather than of a primary organic GI etiology
(8), although this conclusion is not consistent with the
other reported studies that did find increased incidence of
diverse GI problems. A recently published meta-analysis
of GI symptoms in ASD by McElhanon et al. (9) that gath-
ered data from published peer-reviewed journals con-
cluded that GI symptoms are more common in children
with ASD than control children, although they identified
high methodological variability between the studies. In
summary, these studies demonstrate that GI symptoms
are common in children with ASD but that the degree and
nature of these differences have varied across studies.
GI complications in children with ASD may contrib-
ute to the severity of the disorder. One study (10) found
a strong correlation between GI symptoms and autism
severity in a group of 58 children with ASD, consistent
with the CHildhood Autism Risks from Genetics and
Environment (CHARGE) study (7). Abdominal pain, con-
stipation, and/or diarrhea are unpleasant and likely to
produce frustration, decreased ability to concentrate on
tasks, behavior problems, and possibly aggression and
self-abuse, especially in children unable to communicate
their discomfort. These problems also result in a decreased
ability to learn toilet training, leading to increased frus-
tration for the child and their parents/caregivers. However,
given many recent studies that have linked the gut with
the brain (1113), there is also the intriguing possibility
that correlations between ASD and GI symptoms may
not alone be driven by discomfort, but rather by differences
in function of the microbiota, such as the metabolites that
they produce, that may affect neuronal processes.
The cause of these GI problems in ASD is unclear, but it
appears to partly relate to abnormal gut microbiota and
possibly to the excessive use of oral antibiotics which can
alter gut flora. Several studies have reported significantly
higher oral antibiotic use in children with autism versus
typical children (6, 1417). Oral antibiotics were primarily
used for treating otitis media (ear infections), which may
suggest an impaired immune system. Commonly used oral
antibiotics alter the normal gut microbiota (18), which
play an important role in metabolizing plant polysacchar-
ides, promoting GI motility, maintaining water balance,
producing some vitamins, and competing against patho-
genic bacteria. Loss of normal gut flora can result in the
overgrowth of pathogenic flora, which can in turn cause
constipation and other problems. However, it is also worth
noting that in one small study of children with autism,
treatment with the minimally absorbed glycopeptide anti-
biotic vancomycin resulted in short-term improvement in
ASD symptoms, supporting a direct role for the antibiotic-
sensitive gut bacteria in ASD (19).
Distinctive gut microbes have been associated
with ASD
Several small pilot studies of GI bacterial composition in
ASD have been conducted, and although the majority
agree that gut microbiota composition is distinctive in
ASD, these studies have yielded conflicting results as to
the nature and/or extent of GI bacterial community differ-
ences in children with ASD compared to controls (2024).
In work recently described by Kang et al. (21), high-
throughput sequencing of the 16S rDNA gene was used
to compare bacterial composition in fecal samples from
19 children with ASD who had varying GI symptoms and
20 neurotypical controls with minimal GI symptoms. The
presence of autistic symptoms rather than the severity of
GI symptoms was associated with lower abundance of
the bacterial genera Prevotella, Coprococcus, and unclas-
sified Veillonellaceae (pB0.05 after correction for multiple
hypothesis testing) (Fig. 1) and an overall less diverse gut
microbiome (pB0.05). Prevotella, Coprococcus, and Veillo-
nellaceae are intriguingly versatile carbohydrate-degrading
and/or fermenting bacteria, suggesting that the observed
compositional differences can result in differences in the
spectrum of metabolites produced from a given diet.
Fig. 1. Four most differentially abundant genera when children with ASD and neurotypical children are compared (blue box:
neurotypical children; red box: children with ASD). (Figure from Kang et al. (21) under an open access license of PLoS journals called
the Creative Commons Attribution (CC-BY) license.)
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Gut microbes interact heavily through competitive and
cooperative interactions, the latter of which allows for
the metabolism of complex components of our diets. It is
thus of interest to not only look at how ASD associates
with change in the relative abundance of particular types
of bacteria, but also to understand how ASD affects the
complex interaction network that occurs in health. Kang
et al. (21) performed pairwise Pearson correlation tests
across the samples from only the neurotypical individuals
to identify possible microbial interactions that occur in
neurotypical individuals. For instance, with this analysis,
Prevotella copri-like operational taxonomic units (OTUs)
(yellow circles) were connected to multiple different OTUs
mapping to other divergent types of bacteria in the net-
work, showing that their abundance in the gut is often
associated with the abundance of other types of bacteria
(Fig. 2). The network also reflects the degree to which
the observed connections are also present or absent in the
ASD cohort samples (Fig. 2). Although some OTU pairs
had highly correlated relative abundances within both
the neurotypical and independently in the ASD cohort
(blue lines in Fig. 2), many of the relationships that were
observable in neurotypical individuals were not detect-
able in the ASD cohort, either because the OTUs were
both present in the ASD cohort but their relative abun-
dances were not positively correlated (grey and red lines
in Fig. 2), or because at least one OTU in the pair was
absent from the ASD cohort altogether (green lines in
Fig. 2). Thus, the differences in microbiota composition
that occurred with ASD may possibly have led to the
loss of important microbial interactions that result in a
decreased overall diversity and reduced function.
A decreased abundance in Prevotella in children with
ASD was reported when compared with their siblings in
one other study (23), but its prevalence was not signifi-
cantly different in other studies of gut microbiota in ASD
(25). Moreover, differences not found in Kang et al. (21),
such as increases in Clostridium and Sutterella with ASD,
were reported in other studies (20, 26, 27). The study
that detected differences in Sutterella was unique in the
use of mucosal-biopsies (20) rather than fecal samples,
which results in the observation of bacteria at different
prevalence (28).
Observed microbiota differences with ASD have also
been inconsistent with regard to overall microbiota (alpha)
diversity. Kang et al. (21) observed significantly decreased
alpha diversity in children with ASD, which is interesting
in light of the fact that low microbiome diversity has
been associated with increased vulnerability to various
chronic disorders, including a lower resistance to patho-
genic bacteria (29). However, Finegold et al. (30) reported
higher microbial diversity in feces from children with
ASD. The differences in currently reported findings could
be attributed to: the heterology of the disorder, small
sampling sizes, different sample types (e.g. fecal versus
mucosal), different methods of characterizing the micro-
biota (e.g. culture-based versus culture-independent), and
to different bioinformatics analysis methods. These differ-
ences may also reflect different degrees to which the stud-
ies considered potentially confounding factors such as
diet, oral antibiotic use, prebiotics, probiotics, GI pro-
blems, and autistic symptoms. Differences also may reflect
whether siblings or unrelated individuals are used as the
control population. There is one published study that re-
ported to find no significant differences between the gut
microbiome of individuals with ASD and controls that
used only neurotypical siblings as a control population (22).
Interestingly, one study that compared the fecal micro-
biome of children with ASD, neurotypical siblings of
children with ASD, and unrelated neurotypical controls,
found the sibling controls to have a microbiome more
similar to children with ASD than to control subjects
without a neurotypical sibling (23). This may indicate
either a scenario whereby a shared environment produces
the development of a microbiome that leads to autism
in only the genetically susceptible sibling or may also
be related to the shared genetics of siblings. Differences
between cohorts may also reflect the natural human
microbial diversity both within and between individuals.
Inconsistent results with regards to the nature of micro-
biota differences observed across different studies of a
disorder are not unique to the study of ASD. For instance,
there is strong consensus from both human and mouse
studies of obesity, another complex disease with varied
etiology, that microbial composition is altered, but little
consensus on the nature of these changes (31). Overall, the
study of microbiota associations with complex diseases
is difficult and requires large and carefully characterized
subject cohorts.
ASD-associated fecal microbiota evaluated
in a broader context
The prevalence of ASD in developed/Western popula-
tions has risen dramatically over the past decade and a
half (32), leading some to suggest that cultural/ethnic,
environmental, and/or socioeconomic factors in the devel-
oped world are to blame. This theory has been hard to
test because of poor data on ASD prevalence trends in
the developing world and controversy over the degree to
which the observed rise in Western populations is due
to differences in diagnostic criteria (33). However, in one
intriguing study, pervasive developmental disorder (PDD)
prevalence rates in children who were currently living in
Israel was much lower in immigrant Ethiopian children
compared to native Israeli children of Ethiopian heri-
tage (34), giving some evidence that there is an environ-
mental risk factor for PDD that is unique to industrialized
countries. This notion and the fact that the bacterial
genus that was most strongly depleted in the analysis of
the fecal microbiome of children with ASD by Kang et al.
Gut bacteria in children with ASD
Citation: Microbial Ecology in Health & Disease 2015, 26: 26914 - http://dx.doi.org/10.3402/mehd.v26.26914 3
(page number not for citation purpose)
(21), Prevotella, is highly enriched in the fecal microbiota
in populations in Africa including agrarian societies in
Malawi (35) and Burkina Faso (36), and the Hadza hunter
gatherers in Tanzania (37) intrigued us and inspired us
to perform comparative analyses. Since Prevotella is only
one genus in the very diverse gut microbiota and has a
tendency to co-occur with a complex collection of other
bacteria species (38, 39), we wanted to determine whether
Prevotella depletion in children with ASD is an indicator
that the gut microbiome of children with ASD who live in
Fig. 2. Schematic of relationships among pairs at the 97% OTU level. Each grey or yellow circle represents an individual OTU, and
paired OTUs are connected by a line if there is a high positive correlation (Pearson’s R0.8) among neurotypical samples. When paired
OTUs were also present from autistic samples, lines connecting each OTU pair are highlighted either in blue or red depending on their
correlation among autistic samples (either positive or negative correlation, respectively). If at least one OTU in the pair was absent from
autistic samples, the connecting line is colored in green to show the changes in microbial interactions that resulted from the absence of
the OTUs in children with ASD. Prevotella copri-like OTUs are highlighted in yellow to demonstrate how often their abundance is
associated with the other in the network. (Figure from Kang et al. (17) under an open access license of PLoS journals called the Creative
Commons Attribution (CC-BY) license.)
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the United States differs even more from individuals in
the developing world than does the gut microbiome of
neurotypical children in the US, providing evidence of
the gut microbiota as an environmental factor that may
correlate with increased rates of ASD in industrialized
countries.
To directly relate the gut microbiota of children with
ASD to those in agrarian cultures, we combined 16S
rRNA genomic data from the fecal samples sequenced in
Kang et al. (21) from children with ASD and neurotypi-
cal controls, with data from another published study that
used 16S rRNA gene sequencing to survey the fecal
microbiota of individuals from Malawi, the Amazonas
State of Venezuela, and the US (35) (Fig. 3). This latter
paper found the fecal microbiota of individuals in agrar-
ian cultures in Malawi and Venezuela to have a similar
Prevotella-rich composition that was highly divergent from
individuals living in the US.
We first assigned sequences from both studies to 97%
identity (ID) OTUs (clusters in which sequences have
]97% ID over their aligned 16S rRNA genes). This is
a method that is typically used by microbial ecologists
to use 16S rRNA gene sequences to approximate counts
of different species in each sample, where each 97% ID
OTU is a unique species-like unit (40). Specifically, we
assigned our sequences to their closest relative in a data-
base of previously characterized 16S rRNA 97% ID
OTUs (February 4, 2011, Greengenes database) (41) using
UCLUSTref (42) as described in Lozupone et al. (43).
Unassigned sequences, which typically were only B5% of
each sample, were dropped from the analysis. The degree
of difference in the collection of OTUs found in each
pair of samples was then estimated with the unweighted
UniFrac distance metric. UniFrac is similar to algorithms
that estimate distance between communities based on
degree to which species are shared versus unique, such as
the Sorenson index, except that it also considers phyloge-
netic relationships between species when performing the
calculations (44). The relationship between the microbial
diversity in the different samples was visualized using Prin-
cipal Coordinate Analysis (PCoA) (Fig. 3). Only samples
from individuals in Yatsunenko et al. who were between
the ages of 4 and 60 were included in the analysis. We ex-
cluded the samples for children younger than 4 to be
consistent with the population assessed in Kang et al. (21),
in which study participants were 416 years old. Since
the microbiota is highly variable in early life but stabilizes
to an adult-like configuration in children aged 4 and older
(35), we did not exclude the adults in the cohort of
Yatsunenko et al. from the analysis.
As expected based on the analysis conducted by
Yatsunenko et al. (35), the individuals from the US
separated from individuals from Malawi and Venezuela
along PC1 (Fig. 3a). The second PC axis separated US
individuals evaluated in the two different studies from
each other (Fig. 3b). This separation is not surprising
because of methodological differences between the stu-
dies, such as the use of different techniques for extracting
DNA out of the fecal samples and using pyrosequencing
454 versus Illumina technology for the sequencing (43).
Interestingly, along PC1, the samples from children with
ASD from Kang et al. (21) showed a significantly greater
deviation from individuals from agrarian cultures than
did the neurotypical children evaluated in Kang et al. (21)
(Fig. 3b).
The implication of our finding of a ‘hyper-Westerization’
of the fecal microbiota of children with ASD is hard
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Fig. 3. The fecal microbiota of individuals with ASD in the U.S.
shows a greater divergence from individuals in agrarian cultures
compared to neurotypical controls. Unweighted UniFrac PCoA
plot comparing data from children with ASD and neurotypical
control in the U.S. (21) with a global survey of fecal microbial
community composition conducted in individuals from Malawi,
the Amazonas State of Venezuela, and the U.S. (35) (global gut).
(a) Points colored by country of residence. (b) Same plot, but
with points colored by study/ASD status.
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to ascertain. Since Prevotella-prevalence has been linked
with dietary patterns within the US population, with
Prevotella being high in individuals who consumed diets
poor in animal protein and saturated fats and rich in
carbohydrates (as assessed over the prior year with a food
frequency questionnaire) (45), we cannot rule out that
this observation is due to a distinct aspect of the diets of
the children with ASD. However, dietary factors, such
as adherence to a gluten and casein free diet, could not
explain the microbiota differences between children with
ASD and neurotypical controls (21). Another fascinating
idea is that this ‘hyper-Westernization’ could also be linked
with differences in the immune system. This notion is sup-
ported by the observation that individuals with untreated
HIV infection have uniformly high Prevotella and in a
similar meta-analysis with the dataset of Yatsunenko et al.
(35), showed the opposite pattern of children with ASD,
in having a fecal microbiota with a striking resemblance to
that of individuals in the developing world (46). Evalua-
tion of dietary questionnaires indicated that Prevotella-
richness in HIV patients occurred independently of diet
(47). The greater deviation of children with ASD from
individuals with HIV that have a suppressed adaptive
immune system may indicate that this deviation is driven
by individuals with ASD having a hyper-active adaptive
immune system. This is consistent with the observation
that individuals with ASD have high adaptive immune
cytokine responses in stimulations of their peripheral blood
mononuclear cells (48, 49) and high amounts of the Th1
cytokine INF-gamma in the brain (50).
ASD possible gutbrain connection might
be driven by microbial metabolites
Differences reported on microbial diversity and composi-
tion (20, 21, 23, 24) can also be attributed to the fact that
several microorganisms can perform the same function.
This metabolic function can be assessed by measuring
metabolites produced. Several published metabolomics
analyses of urine and fecal metabolites have revealed
differential abundance of bacteria-produced metabolites
that have the potential to directly affect neural processes
(5154). Published urinary metabolites that positively cor-
relate with ASD symptoms include 1) 3-(3-hydroxyphenyl)-
3-hydroxypropionic acid (HPHPA), a probable metabolite
of a tyrosine analog that depletes catecholamines and
causes symptoms of autism, such as stereotypical behav-
ior, hyperactivity, and hyper-reactivity in experimental
animals (51), 2) p-cresol, which can compete with neuro-
transmitters for enzymes and co-factors essential for
sulfonation reactions in the liver (52, 53), and 3) urocanate,
which is regulated by the enzyme urocanase (55). Defi-
ciency of urocanase raises levels of urocanate in the urine
and leads to urocanic aciduria that is associated with
neurological disorders (54). Evidence of a role for bacte-
rial metabolites in eliciting neurobehavioral symptoms
of ASD also comes from a recent study of a maternal
immune activation (MIA) model of ASD in mice, in
which the MIA mice had significant increases in 8% of
322 serum metabolites, with one particular metabolite,
4-ethylphenylsulfate (4EPS), displaying a striking 46-fold
increase. 4EPS is produced by gut bacteria, and treatment
with a particular gut bacterial strain (Bacteroides fragilis)
in early life changed the microbiome structure of MIA
offspring mice, restored levels of 4EPS to normal, and
greatly improved ASD symptoms. Furthermore, injection
of 4EPS into naı¨ve mice resulted in anxiety-like behavior,
providing clear evidence that at least one metabolite pro-
duced by gut bacteria can substantially affect behavior in
mice (56). Although these studies provide evidence that
particular microbially produced metabolites may directly
affect ASD symptoms, an important deficiency in our
current understanding is which microbes may be respon-
sible for the production of which metabolites, how these
microbes interact with each other and with the host, and
how feasible is it to modify ASD symptoms by managing
these microbial interactions. Studies that explore links
between microbiota composition, functional potential (gene
content), gene expression (transcriptomics), metabolomics,
presence and severity of ASD disease symptoms, or neuro-
transmitter signaling in the subject have promise for yielding
a mechanistic understanding of a link between gut micro-
biota and ASD that will pave the way for therapeutics that
target the microbiota in the treatment of ASD.
Prospective
A high rate of GI problems in children with ASD, cor-
relations between symptom severity and GI symptoms
within children with ASD, distinctive profiles of gut
microbes and their metabolites in children with ASD,
and a growing appreciation of a link between the gut
and the brain for many neurological disorders, all point
towards the potential for a role for gut microbiota in
the presentation and severity of ASD symptoms. Further-
more, our observation of a ‘hyper-Westernization’ of the
gut microbiota of children with ASD could indicate that
gut microbiota differences that are driven by unique as-
pects of the Western lifestyle compared to the developing
world lead to the association of unique gut microbiota
composition with ASD. The complexity of the symptoms
and the etiology of ASD coupled with the complexity of
the microbiota and its functions has presented challenges
in establishing the nature of an association between gut
microbiota and ASD, pinning down whether a link even
exists and for which individuals with ASD, and in pro-
ducing a mechanistic understanding of the nature of
this association. Further work in this field that apply
cutting edge ‘omics’ technologies coupled with confirma-
tory experiments in mouse models, as has been done more
extensively with other complex diseases such as obesity,
Rosa Krajmalnik-Brown et al.
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have the promise to address these pressing questions for
the millions of people affected by ASD worldwide.
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